Welcome to our dedicated page for Vaso news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on Vaso stock.
Vaso Corporation (OTCQX: VASO) generates a steady flow of news related to its activities in medical technology, healthcare IT, and professional sales services. The company describes itself as a diversified MedTech and information technology business with operations in managed IT systems and services, healthcare professional sales services, and proprietary medical devices, and its announcements reflect developments across these areas.
News items frequently cover quarterly and annual financial results, where Vaso reports revenue, gross profit, segment performance, and the use of non-GAAP measures such as Adjusted EBITDA. These releases often highlight contributions from its IT, professional sales service, and equipment segments, as well as trends in deferred revenue and subscription revenues.
Another key category of updates involves commercial partnerships and long-term agreements. For example, the company has announced multiple extensions of the sales representation agreement between its VasoHealthcare subsidiary and GE HealthCare. A December 2025 release described the fifth extension of this agreement, which continues VasoHealthcare’s exclusive sales representation of GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments through December 31, 2030.
Vaso’s news flow also includes strategic transactions and corporate actions. In November 2025, the company announced an agreement, subject to certain conditions, to sell its VasoHealthcare IT Corp. subsidiary to Nano-X Imaging Ltd., following a strategic review of its lines of business. Other releases address executive leadership appointments, board roles, and shareholder communications such as CEO letters summarizing achievements and strategic priorities.
Investors and observers who follow VASO news can expect coverage of financial performance, segment updates, long-term sales agreements, divestitures, leadership changes, and shareholder meeting information, providing insight into how the company manages its diversified MedTech and IT portfolio.
Vaso (OTCQX: VASO) has announced the termination of its Business Combination Agreement with Achari Ventures Holdings Corp. I. The company, based in Plainview, N.Y., made this decision on September 18, 2024. Vaso stated that it will continue to pursue opportunities to enhance stockholder value through various means, including:
- Internal growth
- New partnerships
- Strategic investments
The company's focus will remain on medical and IT service companies as it seeks to expand its business and create value for shareholders.
Vaso (OTCQX: VASO) has announced a change in the date of its special stockholders meeting. Originally scheduled for August 26, 2024, the meeting has been adjourned without considering any proposals. The new date is set for September 10, 2024, at 10:00 AM Eastern. The location remains the same: the Lever House at 390 Park Avenue, New York, NY 10022.
The company stated that this postponement, occurring after the Labor Day holiday, is intended to provide more stockholders with the opportunity to attend the meeting in person. This decision reflects Vaso's commitment to maximizing shareholder participation in important corporate decisions.
Vaso (OTCQX: VASO) reported its Q2 2024 financial results, with total revenue of $20.2 million, slightly down from $20.3 million in Q2 2023. The company's IT segment saw a 1% increase, while the professional sales service segment remained flat. The equipment segment experienced a 30% decrease. Gross profit decreased by 4% to $12.2 million. Net income for Q2 2024 was $1.2 million, down from $2.0 million in Q2 2023. Adjusted EBITDA was $1.2 million, compared to $2.1 million a year ago.
Despite lower earnings, Vaso maintains a strong financial position with $25.7 million in cash and cash equivalents. The company's deferred revenue stands at $31.7 million, with a multi-year high backlog of $39.4 million in the IT segment, indicating potential for future growth. Vaso is pursuing a NASDAQ listing through a proposed business combination with Achari Ventures Holdings Corp. I, with a special stockholders meeting scheduled for August 26, 2024.
Vaso (OTCQX: VASO) announced the SEC's approval of Achari Ventures Holdings Corp. I's (NASDAQ: AVHI) S-4 Registration Statement for their proposed business combination. Post-merger, the company will be renamed Vaso Holdings Corp. and listed on NASDAQ. Current Vaso stockholders will own 94-96% of the new entity, valued at approximately $176 million at closing.
Dr. Jun Ma, Vaso's President and CEO, highlighted the company's recent financial performance: annual revenues of $75.2M, $79.3M, and $81.0M in 2021, 2022, and 2023, respectively, with operating incomes of $2.5M, $6.5M, and $4.2M. The company has cash reserves of about $25 million. A special stockholders meeting is scheduled for August 26, 2024, to approve the business combination.
Vaso (OTCQX: VASO) announced its financial results for Q1 2024. Total revenue was $18.7 million, a 1.6% decrease year-over-year primarily due to lower equipment sales. Gross profit fell by 5.6% to $10.9 million, while SG&A expenses rose by 9.4% to $12.2 million. The company reported a net loss of $1.2 million and an adjusted EBITDA of negative $1.3 million. Despite these losses, Vaso's operating cash flow improved by $0.8 million year-over-year, and the company maintained a strong financial position with $26.0 million in cash and short-term investments as of May 3, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.